血小板平均体积是非转移性肾细胞癌的新型预后因素并提升现有评分预测能力
本回顾性分析纳入652例非转移性肾细胞癌患者,评估血小板平均体积的预后价值及其对Leibovich评分预测准确性的改善作用。小血小板体积与较大肿瘤、高Fuhrman分级、肉瘤样成分、组织学肿瘤坏死及血管侵犯相关,并能预测复发和癌特异性生存;加入血小板平均体积后Leibovich评分的c-index提升至0.83(p=0.004)。
要点
- 小血小板体积与较大肿瘤(p=0.043)、高Fuhrman分级(p=0.001)相关。
- 小血小板体积与肉瘤样成分(p<0.0001)、组织学肿瘤坏死(p=0.044)、血管侵犯(p=0.022)相关。
- 小血小板体积可预测复发和癌特异性生存,加入后Leibovich评分c-index=0.83(p=0.004)。
核心结论
- 血小板平均体积是肾细胞癌患者复发和癌特异性死亡的高度显著预测因子。
- 该参数提高了Leibovich预后评分的准确性,能更好地预测局限期肾细胞癌根治性手术切除后的长期结局。
研究设计与样本
- 回顾性分析652例非转移性肾细胞癌患者的记录,评估血小板平均体积的潜在预后价值及其改善辅助临床试验中现有风险评估工具的能力。
- 采用Kaplan-Meier及Marubini和Valsecchi竞争风险估计器评估血小板平均体积与基线协变量及临床结局(复发、肾细胞癌死亡和其他原因死亡)的关联,构建单变量和多变量Cox比例风险模型,应用Harrell c-index检验Leibovich预后评分预测准确性的改善。
主要发现
- 小血小板体积与较大肿瘤相关(p=0.043)。
- 小血小板体积与高Fuhrman分级相关(p=0.001)。
- 小血小板体积与肉瘤样成分相关(p<0.0001)。
- 小血小板体积与组织学肿瘤坏死相关(p=0.044)。
- 小血小板体积与血管侵犯相关(p=0.022)。
关键数值与推荐
- 单变量和多变量分析中,小血小板体积(连续变量和二分类变量)准确预测复发性肾细胞癌和癌特异性生存。
- 将血小板平均体积加入Leibovich预后评分后,其判别性能改善(c-index=0.83,p=0.004)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The average size of blood platelets determined by mean platelet volume might represent a biologically meaningful parameter in carcinogenesis and potentially serve as a novel prognostic biomarker in renal cell carcinoma. MATERIALS AND METHODS: In this retrospective analysis of the records of 652 patients we evaluated the potential prognostic value of mean platelet volume and its ability to improve existing risk assessment tools used in adjuvant clinical trials in nonmetastatic renal cell carcinoma cases. Associations of mean platelet volume with baseline covariates and clinical outcomes (recurrence, and death from renal cell carcinoma and other causes) were assessed with the competing risk estimators of Kaplan-Meier, and Marubini and Valsecchi, respectively. Univariable and multivariable Cox proportional hazard models were constructed. The Harrell c-index was applied to test improvements in the predictive accuracy of the established Leibovich prognosis score. RESULTS: Small platelet volume was associated with large tumors (p = 0.043), high Fuhrman grade (p = 0.001), sarcomatoid components (p <0.0001), histological tumor necrosis (p = 0.044) and vascular invasion (p = 0.022). On univariable and multivariable analyses small platelet volume accurately predicted recurrent renal cell carcinoma (continuously and binary coded) and cancer specific survival. Adding mean platelet volume to the Leibovich prognosis score improved its discriminative performance (c-index = 0.83, p = 0.004). CONCLUSIONS: Mean platelet volume represented a highly significant predictor of recurrence and cancer specific death in patients with renal cell carcinoma. This parameter improved the accuracy of the Leibovich prognosis score to better predict long-term outcomes in localized renal cell carcinoma cases after curative surgical resection.
引用
- Seles M, Posch F, Pichler GP, et al. Blood Platelet Volume Represents a Novel Prognostic Factor in Patients with Nonmetastatic Renal Cell Carcinoma and Improves the Predictive Ability of Established Prognostic Scores. J Urol. 2017. PMID: 28716649. doi:10.1016/j.juro.2017.07.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。